MiNK Therapeutics, Inc. (INKT)
Summary
Here's Why You Should Add INKT Stock to Your Portfolio Now
MiNK advances agenT-797 across respiratory, oncology and immune disease studies while expanding its next-generation engineered iNKT pipeline.
MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript
MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript
MiNK Therapeutics Q1 Earnings Call Highlights
MiNK Therapeutics NASDAQ: INKT said it is advancing its off-the-shelf invariant natural killer T cell therapy platform into a randomized clinical program for severe acute lung injury and acute respiratory distress syndrome, while also reporting first-quarter 2026 financial results that management said support at least 12 months of operating runway.
MiNK Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Ana-Maria Ignat Covestor Ltd | 119 | $994.41 | $1,281.63 | $287.22 | 28.88% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 10 | $105 | $107.7 | $2.7 | 2.57% |
 Jay Annis Annis Gardner Whiting Capital Advisors, LLC | 200 | $2,106 | $2,154 | $48 | 2.28% |
MiNK Therapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JA Jack Allen Baird | - | - | - | - | - |
| EB Emily Bodnar HC Wainwright & Co. | -376,041.94 | $4.56M | $4.16M | $400,735.76 | 8.78% |
MiNK Therapeutics, Inc. (INKT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has MiNK Therapeutics, Inc. ever had a stock split?
MiNK Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jennifer S. Buell CEO | NASDAQ (CM) Exchange | 603693201 CUSIP |
| US Country | 15 Employees | - Last Dividend | 28 Jan 2025 Last Split | 15 Oct 2021 IPO Date |
Overview
MiNK Therapeutics, Inc. is a pioneering biopharmaceutical firm focused on the forefront of cancer and immune-mediated disease treatment. Operating from its base in New York, New York, MiNK Therapeutics leverages its expertise in the field of invariant natural killer T (iNKT) cell therapies. As a clinical-stage enterprise, its dedication lies in advancing these innovative therapies from discovery through to commercialization. Initially known as AgenTus Therapeutics, Inc., the company underwent a rebranding to better align with its focused approach towards iNKT cell therapies. Since its establishment in 2017, MiNK Therapeutics has been an integral part of the Agenus Inc. family, benefiting from the parent company's vast resources and expertise in the biopharmaceutical sector.
Products and Services
- AGENT-797
At the core of MiNK Therapeutics’ product line is AGENT-797, a groundbreaking allogeneic iNKT cell therapy. This off-the-shelf therapeutic candidate stands out for its application in treating a plethora of myeloma diseases and solid tumors. Currently in Phase 1 clinical trials, AGENT-797 exemplifies MiNK Therapeutics’ commitment to unleashing the potential of iNKT cell therapies across various disease spectrums. Its development underscores the company's aim at delivering novel, effective treatments that can transform the therapeutic landscape for cancer and other immune-mediated diseases.
